Johnson & Johnson: Tracking Well Above The Industry
Johnson & Johnson shows strong progress in oncology with Darzalex sales and regulatory filings, leading to a 'Buy' rating ...
pharmaphorum2h
GSK hails survival data with revived myeloma drug Blenrep
GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an ...
Assetmark Inc. Has $2.01 Million Stock Position in Genmab A/S (NASDAQ:GMAB)
Assetmark Inc. boosted its stake in shares of Genmab A/S (NASDAQ:GMAB – Free Report) by 16.2% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 82,629 shares of ...
Genmab price target lowered to DKK 2,250 from DKK 2,500 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Genmab (GMAB) to DKK 2,250 from DKK 2,500 and keeps a Buy rating on the shares.
pharmaphorum23h
Sanofi wins appeal in spat with NICE over Sarclisa
The drugmaker has won an appeal against NICE's recent final draft guidance on Sarclisa (isatuximab) as a regimen alongside ...
The New York Times22h
New York Times - Top Stories
At Mar-a-Lago, ‘Uncle’ Elon Musk Puts His Imprint on the Trump Transition He’s on the patio. He’s on the golf course. Everywhere President-elect Trump looks, there is the world’s richest ...
ENDPOINTS NEWS1h
GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta
GSK reported positive survival data for Blenrep combined with bortezomib and dexamethasone in multiple myeloma DREAMM-7 trial, outperforming daratumumab combination therapy. GSK plans US relaunch in ...